Natco Pharma Q3 Results 2025: As per the Natco Pharma Q3 Results 2025, Revenue fell 38% year over year as a result of a decline in the formulations (domestic) sector and a lack of Revilimid sales. Increased R&D costs caused EBITDA to drop 86% and margins to drop 27%. Let’s unleash all the details regarding Natco pharma Q3 results 2025 in this article.
Brief of Natco Pharma Limited
In 1981, Natco Pharma Ltd. was established in Hyderabad with an INR 3.3 million startup capital. Since its humble beginnings as a single unit employing 20 people, Natco has grown to eight production facilities located throughout India, each having its own state-of-the-art research labs and capabilities in areas such as new drug development. Today, the Natco family employs almost 4,500 people, and they are frequently listed as one of India’s fastest-growing pharmaceutical enterprises. For its inventiveness in pharmaceutical R&D, Natco is widely acknowledged.
Natco Pharma Q3 Results 2025
The lack of Revilimid sales in the US and a decline in the local formulations business caused Natco Pharma to fail consensus Q3 projections on both the EBITDA margin and revenue fronts, according to stock analysts. As a result, stocks of Natco Pharma have plunged by more than 15% just after the results of December quarter. Thus, it is essential to analyze the Natco Pharma Q3 Results 2025. Given below are the key details of Natco Pharma Q3 Results 2025:
- A net profit (consolidated) of ₹ 212.7 cr. was reported by the corporation in the third quarter of the preceding fiscal year.
- The third quarter’s total expenses were ₹ 487.4 crore, down from ₹ 539.3 crore during the same period last year.
- Comparing the third quarter of this fiscal year to the same period last year, formulation exports decreased to ₹ 285.8 crore from ₹ 605.6 crore. According to NATCO Pharma’s investor presentation, domestic market sales also decreased to ₹ 96.1 crore from ₹ 99.4 crore during the same period last year.
The market value of the company is Rs 21,791 crore and many analysts recommends a ‘hold’ for this share despite disturbing Natco Pharma Q3 results 2025. The stock’s average target price is Rs 1,349. This represents an 11% increase over current market levels.
Conclusion
NATCO Pharma’s stock plunges 10% to a 52-week low, continuing its decline for the sixth consecutive session. What future holds for the company, only time will tell but at present it would not be wrong to say that the Natco Pharma Q3 results 2025 pretty much states the actual position of the company financially that is very weak at the moment.
For additional information, visit the Angelone app, which allows you to start investing right away and setup your Demat account with only one swipe.
Disclaimer: Demat Dive is not giving any buying advice on any stock. Consult a SEBI-registered advisor before investing anywhere.